KEFEA: Re-elected president
Mikellis stressed that KEFEA’s priorities in the near future will be the implementation of a viable and effective National Health Scheme in Cyprus and the realisation of European directive and falsified medicines. Jacqueline Anastassiades, Managing Director of Merck Sharp & Dohme (MSD) in Cyprus, was elected as vice president.
KEFEA, founded in 2006, represents the pharmaceutical industry in Cyprus with the aim to implement a sustainable healthcare system for all Cypriots. It’s members are relevant healthcare stakeholders.
Mologen: Preparing for market launch
Baumann will become a member of the Executive Board and will be responsible for research, preclinical and clinical development, approval and Mologen’s clinical strategy. Until his switch to Mologen, Baumann will continue working as CMO for the biotech German company Noxxon Pharma AG. Prior to joining Noxxon in February 2011, Baumann was Chief Scientific Officer of Focus Clinical Drug Development GmbH and previously active in various research and development positions at Roche and Boehringer Mannheim.
Genmab: Pushing for growth
Klimovsky will be responsible for Genmab’s product development strategy in line with the company's corporate strategy. Most recently, she served as Senior Vice President and Global Head, Oncology Clinical Development, at Novartis. Klimovsky is a haematologist by training with extensive experience in various roles at BMS, Merck and Novartis.
Klimovsky will be based at the company's Princeton, United States location, whilst travelling regularly to the company's locations in Copenhagen, Denmark and Utrecht, The Netherlands.
One Nucleus: Seasoned Director
Summerton has over 25 years’ experience in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service provider organisations. For 18 years, she worked at AstraZeneca, where she held a variety of roles, most recently Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team. She has a first degree and PhD from Cambridge UK, and held a NATO post-doctoral Fellowship tenured at University of California, San Francisco.
Medherant: Chair for the clinic
Between 2006 and 2010, Cunningham was at SkyePharma plc, initially as Chief Operating Officer and subsequently as Chief Executive Officer. He holds a Medical Degree from St Mary's, Imperial College London.
Applied Photophysics: Risen through the ranks
Madden holds a BA in law and accountancy from Manchester University. Previously, she was Finance Director at Farfield Group Limited and Global Service Manager at Biolin Scientific AB. Before this, she spent 11 years at KPMG.